Clinical trials: Demyelinating Disease
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
- Trial name
- NCT02200770
- Testing
- Inebilizumab
- Where
- 98 sites in United States, Australia and 23 more
- Volunteers
- 231 people
- Sponsor
- MedImmune LLC
Relapsing Remitting Multiple Sclerosis
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.
- Trial name
- NCT01541618
- Testing
- MSDX Complex-1 Biomarker test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MSDx, Inc.
Multiple Sclerosis, Relapsing-remitting
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
This is a randomized, multicenter, parallel-group, open-label study comparing the tolerability of Rebif® injections (44 microgram [mcg] administered subcutaneously three times a week) with and without Rebiject™Mini, an…
- Trial name
- NCT00292253
- Testing
- Rebif® via Rebiject™Mini, Rebif® via manual injections
- Volunteers
- 1,883 people
- Sponsor
- EMD Serono
Multiple Sclerosis
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
This is a prospective, multicenter, observational, non-interventional study (NIS) in patients with Multiple Sclerosis (MS) and routinely assessed serum neurofilament light (sNfL) values in Germany
- Trial name
- FILAXOS (NCT06551519)
- Testing
- ofatumumab, DMT category 1
- Where
- 82 sites in Germany
- Volunteers
- 519 people
- Sponsor
- Novartis Pharmaceuticals
Non-Active Secondary Progressive Multiple Sclerosis
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
This is an open-label, intermediate-size patient population expanded access treatment study utilizing 1 dose level of nasal Foralumab (50 µg/dosing day) with the possibility of increasing to 100 µg/dosing day.
- Trial name
- NCT06802328
- Testing
- Foralumab TZLS-401 50 µg
- Where
- United States
- Sponsor
- Tiziana Life Sciences LTD
Multiple Sclerosis, RRMS
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
This is a 3-year, pharmacologically non-interventional study to evaluate OCT as an outcome measure in patients with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- OCTIMS (NCT02907281)
- Testing
- Observational
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
The primary objectives of this study were: to evaluate the effect of Tysabri® (natalizumab) on antibody responses after immunization with a neoantigen (keyhole limpet hemocyanin [KLH]) and a recall antigen (tetanus toxoid [Td])…
- Trial name
- NCT00536120
- Testing
- BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Transverse Myelitis
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects…
- Trial name
- NCT03887273
- Testing
- Q-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Q Therapeutics, Inc.
Multiple Sclerosis, Neurogenic Bladder
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
- Conditions
- Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases
- Trial name
- SONIC (NCT00629642)
- Testing
- Solifenacin Succinate, Oxybutynin Hydrochloride
- Where
- 39 sites in Australia, Belgium and 9 more
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma Inc
Relapsing Forms of Multiple Sclerosis
Plegridy Observational Program
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to assess the overall long-term…
- Trial name
- POP (NCT02230969)
- Testing
- peginterferon beta-1a
- Where
- 152 sites in United States, Australia and 12 more
- Volunteers
- 1,208 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration…
- Trial name
- FREVIVA (NCT06141486)
- Testing
- Frexalimab, MRI contrast-enhancing agents
- Where
- 311 sites in United States, Argentina and 25 more
- Volunteers
- 943 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis
Study Title: A Serologic Study to Correlate b-IFN NAb titers to b-IFN Induced Biomarker Response in Patients with Multiple Sclerosis Objectives: Subjects currently on any of the three b-IFN preparations (Avonex (Interferon b-1a…
- Trial name
- NCT00288990
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- Biogen
Multiple Sclerosis
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT00484536
- Testing
- CDP323
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 232 people
- Sponsor
- UCB Pharma
Multiple Sclerosis
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to Multiple Sclerosis.
- Trial name
- NCT00381264
- Testing
- Cesamet™ (nabilone)
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- NEMA Research, Inc.
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Multiple Sclerosis
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
- Trial name
- BETAPREDICT (NCT02486640)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046), Betaconnect Autoinjector
- Where
- Germany
- Volunteers
- 162 people
- Sponsor
- Bayer
Multiple Sclerosis
Study of the Tolerability and Pharmacokinetics of Oral Doses of SAR442168 With a Food Effect Investigation in Healthy Adult Participants
This is a randomized, placebo-controlled, four-part, Phase I, first in human (FIH) study to assess the tolerability and pharmacokinetics (PK) of ascending single and 14-day repeated oral doses of SAR442168 with a food effect…
- Trial name
- NCT06106074
- Testing
- Tolebrutinib
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Sanofi
Relapsing-remitting Multiple Sclerosis
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)
The purpose of this single visit extension study is to explore immune status in RRMS patients treated for at least 48 months with fingolimod.
- Trial name
- NCT02720107
- Testing
- fingolimod
- Where
- 26 sites in Germany
- Volunteers
- 133 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.